Resolution of chronic inflammation as a new adjunctive approach in schizophrenia treatment

Publication date: Available online 26 March 2020Source: Brain, Behavior, and ImmunityAuthor(s): Alexander Kalinkovich, Michael Pouyrovsky, Regina Nasyrova, Gregory Livshits
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 28 May 2020Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Matsuhiko Oka, Koki Ito, Minori Koga, Ichiro Kusumi
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - Category: Psychiatry Source Type: research
CONCLUSION: Olanzapine was considered the most cost-effective drug for the first-line treatment of schizophrenia in Brazil. Aripiprazole was dominated by risperidone and was not considered cost-effective against olanzapine. IMPLICATIONS FOR HEALTH CARE PROVISION AND USE: This work demonstrated, using a price adjustment process, that there is no viable price that would make aripiprazole cost-effective for incorporation in the Brazilian public health system in the first-line of treatment of schizophrenia. The drug can be useful in specific cases, since individual variability of response to antipsychotic drugs is importan...
Source: Journal of Mental Health Policy and Economics - Category: Psychiatry Tags: J Ment Health Policy Econ Source Type: research
Publication date: Available online 28 May 2020Source: Neuroscience LettersAuthor(s): Frederico Rogério Ferreira, Nathalia Souza Barros de Moura, Lucas Hassib Camina, Thatiane Rebelo Pombo
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Authors: Artukoglu BB, Li F, Szejko N, Bloch MH Abstract OBJECTIVE: To examine the efficacy of pharmacologic treatments for tardive dyskinesia (TD). DATA SOURCES: PubMed was searched on December 12, 2017, for randomized, placebo-controlled trials examining the treatment of TD using the search terms (drug-induced dyskinesia OR tardive dyskinesia) AND (psychotic disorders OR schizophrenia). STUDY SELECTION: Studies were included if they examined tardive dyskinesia treatment as the primary outcome and were randomized and placebo-controlled trials. DATA EXTRACTION: The effect size (standard mean difference)...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Authors: Tréhout M, Leroux E, Bigot L, Jego S, Leconte P, Reboursière E, Morello R, Chapon PA, Herbinet A, Quarck G, Dollfus S Abstract Patients with schizophrenia (SZ) have a high level of cardiovascular morbidity and some clinical symptoms of illness remain resistant to pharmacological approaches. A large number of studies support the effectiveness of physical activity (PA) in SZ. The aims of this trial is to assess the effects of a remote, web-based adapted PA program (e-APA) compared to a health education program (e-HE) on brain plasticity in SZ and healthy volunteers (HV) and on psychiatric, neur...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
Authors: Ma CC, Kao YC, Tzeng NS, Chao CY, Chang CC, Chang HA Abstract Varying degrees of impaired clinical insight in schizophrenia differentially impact medication adherence and clinical outcomes, prompting in-depth investigations of the deficits. Research is scarce on the differences in peripheral physiological markers between varying degrees of impaired insight. The aims of this study were to examine the differences in (1) resting-state high-frequency heart rate variability (HF-HRV) and (2) crucial clinical outcomes between schizophrenia patients with varying degrees of insight impairment as measured by the Pos...
Source: Asian Journal of Psychiatry - Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
Authors: Chang J, Kim JA, Kim K, Choi S, Kim SM, Nam YY, Park S, Goo AJ, Park SM Abstract BACKGROUND: The effect of antipsychotics adherence on the risk of cardiovascular disease (CVD) among schizophrenia patients has not been studied. While antipsychotic adherence is favorable for all-cause mortality, its association with CVD incidence is unclear due to the potential risk of CVD caused by antipsychotics. METHODS: Using the Korean National Health Insurance Service Database, we constructed a case-cohort of 80,581 newly-diagnosed schizophrenia patients between 2004 and 2013 from a cohort of all Koreans 20-40 year...
Source: Asian Journal of Psychiatry - Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
No abstract available
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Quick Recertification Series Source Type: research
Authors: Bugyi B, Kengyel A Abstract Myosin XVI (Myo16), a vertebrate-specific motor protein, is a recently discovered member of the myosin superfamily. The detailed functionality regarding myosin XVI requires elucidating or clarification; however, it appears to portray an important role in neural development and in the proper functioning of the nervous system. It is expressed in the largest amount in neural tissues in the late embryonic-early postnatal period, specifically the time in which neuronal cell migration and dendritic elaboration coincide. The impaired expression of myosin XVI has been found lurking in t...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Catatonia was first described by Karl Ludwig Kahlbaum in 1874, occurring in association with other psychiatric and medical disorders. However, in the nineteenth century the disorder was incorrectly classified as a subtype of schizophrenia. This misclassification persisted until the publication of DSM-5 in 2013 when important changes were incorporated. Although the etiology is unknown, disrupted gamma-aminobutyric acid has been proposed as the underlying pathophysiological mechanism. Key symptoms can be identified under 3 clinical domains: motor, speech, and behavioral. Benzodiazepines and electroconvulsive therapy are the ...
Source: Child and Adolescent Psychiatric Clinics of North America - Category: Psychiatry Authors: Source Type: research
More News: Brain | Neurology | Schizophrenia